New insights into the pharmacodynamic and pharmacokinetic properties of statins

Alberto Corsini, Stefano Bellosta, Roberta Baetta, Remo Fumagalli, Rodolfo Paoletti, Franco Bernini

Research output: Contribution to journalArticle

645 Citations (Scopus)

Abstract

The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)413-428
Number of pages16
JournalPharmacology and Therapeutics
Volume84
Issue number3
DOIs
Publication statusPublished - Dec 1999

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
fluvastatin
Pharmacokinetics
Simvastatin
Pravastatin
Lovastatin
Cholesterol
Drug Interactions
Cyclosporine
Biological Availability
Mibefradil
Macrophages
Cytochrome P-450 CYP3A
Mevalonic Acid
Rhabdomyolysis
Myositis
Terpenes
Metalloproteases
Enzyme Inhibitors
Hypercholesterolemia

Keywords

  • HMG-CoA reductase inhibitors
  • Pharmacodynamics
  • Pharmacokinetics
  • Statins

ASJC Scopus subject areas

  • Pharmacology

Cite this

New insights into the pharmacodynamic and pharmacokinetic properties of statins. / Corsini, Alberto; Bellosta, Stefano; Baetta, Roberta; Fumagalli, Remo; Paoletti, Rodolfo; Bernini, Franco.

In: Pharmacology and Therapeutics, Vol. 84, No. 3, 12.1999, p. 413-428.

Research output: Contribution to journalArticle

Corsini, Alberto ; Bellosta, Stefano ; Baetta, Roberta ; Fumagalli, Remo ; Paoletti, Rodolfo ; Bernini, Franco. / New insights into the pharmacodynamic and pharmacokinetic properties of statins. In: Pharmacology and Therapeutics. 1999 ; Vol. 84, No. 3. pp. 413-428.
@article{6c02dd98761c481a90d912299c2371ff,
title = "New insights into the pharmacodynamic and pharmacokinetic properties of statins",
abstract = "The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy. Copyright (C) 1999 Elsevier Science Inc.",
keywords = "HMG-CoA reductase inhibitors, Pharmacodynamics, Pharmacokinetics, Statins",
author = "Alberto Corsini and Stefano Bellosta and Roberta Baetta and Remo Fumagalli and Rodolfo Paoletti and Franco Bernini",
year = "1999",
month = "12",
doi = "10.1016/S0163-7258(99)00045-5",
language = "English",
volume = "84",
pages = "413--428",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - New insights into the pharmacodynamic and pharmacokinetic properties of statins

AU - Corsini, Alberto

AU - Bellosta, Stefano

AU - Baetta, Roberta

AU - Fumagalli, Remo

AU - Paoletti, Rodolfo

AU - Bernini, Franco

PY - 1999/12

Y1 - 1999/12

N2 - The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy. Copyright (C) 1999 Elsevier Science Inc.

AB - The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy. Copyright (C) 1999 Elsevier Science Inc.

KW - HMG-CoA reductase inhibitors

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=0032805692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032805692&partnerID=8YFLogxK

U2 - 10.1016/S0163-7258(99)00045-5

DO - 10.1016/S0163-7258(99)00045-5

M3 - Article

C2 - 10665838

AN - SCOPUS:0032805692

VL - 84

SP - 413

EP - 428

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -